Literature DB >> 2258629

A possible role for transforming growth factor-beta in systemic sclerosis.

E A Smith1, E C LeRoy.   

Abstract

The cause of systemic sclerosis remains unknown, but cellular and molecular mechanisms possibly responsible for the characteristic clinical manifestations of fibrosis and vascular damage (Raynaud's phenomenon, telangiectasis, digital infection, and renal arteriopathy) are becoming understood in greater detail. One possibly important cytokine is transforming growth factor-beta (TGF-beta); its involvement is reviewed here. With regard to vascular lesions, TGF-beta has variably been shown to inhibit endothelial cell growth in vitro but to promote angiogenesis in vivo, a paradox that remains unresolved. Nonetheless, an injurious activity of TGF-beta on microvascular endothelial cells could help to explain the intimal proliferation and microvascular obliteration seen. Whether as a result of or as a cause of endothelial cell damage, platelet activation has been well documented in systemic sclerosis and the platelet alpha granule pool contains a large quantity of TGF-beta. TGF-beta is also produced by activated macrophages and T cells, both of which are known to occur within systemic sclerosis lesions. An important effect of TGF-beta is its stimulation of fibroblast collagen and fibronectin synthesis and their deposition into the extracellular matrix. Stimulation by TGF-beta may therefore account for the fibrosis seen in the dermis and in the internal organs. Direct evidence of TGF-beta involvement in systemic sclerosis is scanty, and awaits discovery of either an abnormal expression of or response to TGF-beta. The biologic effects of TGF-beta appear to be regulated at the level of activation from a latent polypeptide precursor form. Descriptions of the importance of this cytokine in pathologic conditions will need to account for this activation and its regulation. Nonetheless, the physiologic effects so far attributed to TGF-beta make its involvement in systemic sclerosis an attractive possibility to explain some of the manifestations of this enigmatic disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2258629     DOI: 10.1111/1523-1747.ep12874998

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

1.  MicroRNA array analysis of microRNAs related to systemic scleroderma.

Authors:  Haitao Li; Rongya Yang; Xin Fan; Tingmin Gu; Zhili Zhao; Dongqing Chang; Wenling Wang; Congmin Wang
Journal:  Rheumatol Int       Date:  2010-10-30       Impact factor: 2.631

2.  The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts.

Authors:  A Leask; S Sa; A Holmes; X Shiwen; C M Black; D J Abraham
Journal:  Mol Pathol       Date:  2001-06

3.  Role of protein kinase C-delta in the regulation of collagen gene expression in scleroderma fibroblasts.

Authors:  S A Jimenez; S Gaidarova; B Saitta; N Sandorfi; D J Herrich; J C Rosenbloom; U Kucich; W R Abrams; J Rosenbloom
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  Evaluation of membrane-bound and soluble forms of human leucocyte antigen-G in systemic sclerosis.

Authors:  P Contini; S Negrini; G Murdaca; M Borro; F Puppo
Journal:  Clin Exp Immunol       Date:  2018-05-23       Impact factor: 4.330

5.  Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles.

Authors:  L D Carbone; K J Warrington; K D Barrow; M Pugazhenthi; M A Watsky; G Somes; J Ingels; A E Postlethwaite
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

6.  Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome.

Authors:  A L Bennett; C C Chao; S Hu; D Buchwald; L R Fagioli; P H Schur; P K Peterson; A L Komaroff
Journal:  J Clin Immunol       Date:  1997-03       Impact factor: 8.317

7.  A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity.

Authors:  Jennifer L Sargent; Ausra Milano; Swati Bhattacharyya; John Varga; M Kari Connolly; Howard Y Chang; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2009-10-08       Impact factor: 8.551

8.  CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth.

Authors:  Claudia Capparelli; Diana Whitaker-Menezes; Carmela Guido; Renee Balliet; Timothy G Pestell; Anthony Howell; Sharon Sneddon; Richard G Pestell; Ubaldo Martinez-Outschoorn; Michael P Lisanti; Federica Sotgia
Journal:  Cell Cycle       Date:  2012-06-15       Impact factor: 4.534

Review 9.  The aetiopathogenesis of systemic sclerosis: thick skin--thin hypotheses. The Parkes Weber Lecture 1994.

Authors:  C M Black
Journal:  J R Coll Physicians Lond       Date:  1995 Mar-Apr

10.  Radiation-induced skin injury in the animal model of scleroderma: implications for post-radiotherapy fibrosis.

Authors:  Sanath Kumar; Andrew Kolozsvary; Robert Kohl; Mei Lu; Stephen Brown; Jae Ho Kim
Journal:  Radiat Oncol       Date:  2008-11-24       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.